HPMA-based polymer conjugates with drug combination

详细信息    查看全文

• 作者：Hana Krakovič ; ová ; Tomá ; š ; Etrych ; Karel Ulbrich
• 关键词：HPMA copolymer ; Drug carriers ; Doxorubicin ; Dexamethason ; Combination therapy ; Anti-tumor activity ; Carboxyesterase
• 刊名：European Journal of Pharmaceutical Sciences
• 出版年：2009
• 出版时间：28 June 2009
• 年：2009
• 卷：37
• 期：3-4
• 页码：405-412
• 全文大小：530 K

文摘

Synthesis and physico-chemical behavior of new polymer–drug conjugates intended for the treatment of cancer were investigated. In the polymer conjugate with the expected dual therapeutic activity, two drugs, a cytostatic agent doxorubicin (DOX) and anti-inflammatory drug dexamethason (DEX) were covalently attached to the same polymer backbone via hydrolytically labile pH-sensitive hydrazone bonds. The precursor, a copolymer of N-(2-hydroxypropyl)methacrylamide (HPMA) bearing hydrazide groups randomly distributed along the polymer chain, was conjugated with DOX (through its C13 keto group) or with a keto ester (DEX). Two derivatives of DEX, 4-oxopentanoate and 4-(2-oxopropyl)benzoate esters, were synthesized and employed for conjugation reaction. As a control, also a few polymer conjugates containing only a single drug (DOX or DEX) attached to the polymer carrier were synthesized. Physico-chemical properties of the polymer conjugates strongly depend on the attached drug, spacer structure and the drug content. Polymer–drug conjugates incubated in buffers modeling intracellular environment released the drug (DOX) or a drug derivatives (DEX) at the rate significantly exceeding the release rate observed under conditions mimicking situation in the blood stream. Incubation of the DEX conjugates in a buffer containing carboxyesterase resulted in complete ester hydrolysis thus demonstrating susceptibility of the system to release free active drug in the two-step release profile.